Abstract:Abstract Background Human Tau (hTau) accumulation and synapse loss are two pathological hallmarks of tauopathies. However, whether and how hTau exerts toxic effects on synapses remain elusive. Methods Mutated hTau (P301S) was overexpressed in the N2a cell line, primary hippocampal neurons and hippocampal CA3. Western blotting and quantitative polymerase chain reaction were applied to examine the protein and mRNA levels of synaptic proteins. The protein interaction was tested by co‐immunoprecipitation and proximity ligation assays. Memory and emotion status were evaluated by a series of behavioural tests. The transcriptional activity of nuclear factor‐erythroid 2–related factor 2 (NRF2) was detected by dual luciferase reporter assay. Electrophoresis mobility shift assay and chromosome immunoprecipitation were conducted to examine the combination of NRF2 to specific anti‐oxidative response element (ARE) sequences. Neuronal morphology was analysed after Golgi staining. Results Overexpressing P301S decreased the protein levels of post‐synaptic density protein 93 (PSD93), PSD95 and synapsin 1 (SYN1). Simultaneously, NRF2 was decreased, whereas Kelch‐like ECH‐associated protein 1 (KEAP1) was elevated. Further, we found that NRF2 could bind to the specific AREs of DLG2, DLG4 and SYN1 genes, which encode PSD93, PSD95 and SYN1, respectively, to promote their expression. Overexpressing NRF2 ameliorated P301S‐reduced synaptic proteins and synapse. By means of acetylation at K312, P301S increased the protein level of KEAP1 via inhibiting KEAP1 degradation from ubiquitin–proteasome pathway, thereby decreasing NRF2 and reducing synapse. Blocking the P301S–KEAP1 interaction at K312 rescued the P301S‐suppressed expression of synaptic proteins and memory deficits with anxiety efficiently. Conclusions P301S‐hTau could acetylate KEAP1 to trigger synaptic toxicity via inhibiting the NRF2/ARE pathway. These findings provide a novel and potential target for the therapeutic intervention of tauopathies.

Synaptic Released Zinc Promotes Tau Hyperphosphorylation by Inhibition of Protein Phosphatase 2A (PP2A)

Tau Acts in Concert With Kinase/Phosphatase Underlying Synaptic Dysfunction

Zinc enhances liquid-liquid phase separation of Tau protein and aggravates mitochondrial damages in cells

Pathological Concentration of Zinc Dramatically Accelerates Abnormal Aggregation of Full-Length Human Tau and Thereby Significantly Increases Tau Toxicity in Neuronal Cells.

Zinc binding directly regulates tau toxicity independent of tau hyperphosphorylation.

ChemInform Abstract: Tau Protein Associated Inhibitors in Alzheimer Disease

P301S‐hTau Acetylates KEAP1 to Trigger Synaptic Toxicity Via Inhibiting NRF2/ARE Pathway: A Novel Mechanism Underlying Htau‐induced Synaptic Toxicities

The role of pathological tau in synaptic dysfunction in Alzheimer’s diseases

Low Micromolar Zinc Accelerates the Fibrillization of Human Tau Via Bridging of Cys-291 and Cys-322*

Zinc exacerbates tau-induced Alzheimer-like pathology in C57BL/6J mice

Overexpression of 14-3-3ζ Promotes Tau Phosphorylation at Ser262 and Accelerates Proteosomal Degradation of Synaptophysin in Rat Primary Hippocampal Neurons

Tau Protein Associated Inhibitors in Alzheimer Disease

Dephosphorylation Passivates the Seeding Activity of Oligomeric Tau Derived From Alzheimer’s Brain

Modulation of Tau Pathology in Alzheimer's Disease by Dietary Bioactive Compounds

Tau accumulation activates STAT1 triggering memory deficits via suppressing NMDA receptor expression

NAP Protects against Tau Hyperphosphorylation Through GSK3.

Tau Accumulation Triggers STAT 1‐dependent Memory Deficits by Suppressing NMDA Receptor Expression

The Synaptic Vesicle Protein 2a Interacts with Key Pathogenic Factors in Alzheimer’s Disease: Implications for Treatment

Tau accumulation triggers STAT1-dependent memory deficits by suppressing NMDA receptor expression

Discrepancy of synaptic and microtubular protein phosphorylation in the hippocampus of APP/PS1 and MAPT×P301S transgenic mice at the early stage of Alzheimer's disease

Role of Microtubule-Associated Protein Tau Phosphorylation in Alzheimer’s Disease